In focus
Latest feed
Novo Nordisk: The High-Stakes Balancing Act Between Price and Scale
The Pharma Giants' Bold Leap: Novo Nordisk and Eli Lilly Eyeing Direct Sales of Obesity Drugs to Employers
Novo Nordisk Shifts Focus: Why the Cell Therapy Unit is Closing Its Doors
Cagrisema: Novo Nordisk's Dual-Action Powerhouse Poised to Revolutionize Obesity Treatment
